301. Dihydropteridine reductase deficiency in man: from biology to treatment.
- Author
-
Ponzone A, Spada M, Ferraris S, Dianzani I, and de Sanctis L
- Subjects
- Female, Humans, Incidence, Infant, Newborn, Italy epidemiology, Male, Neonatal Screening, Research, Risk Factors, Sex Distribution, Genetic Predisposition to Disease, Phenylketonurias epidemiology, Phenylketonurias genetics, Phenylketonurias therapy
- Abstract
In 1975, dihydropteridine reductase (DHPR) deficiency was first recognized as a cause of tetrahydrobiopterin (BH(4)) deficiency, leading to hyperphenylalaninemia (HPA) and impaired biogenic amine deficiency. So far, more than 150 patients scattered worldwide have been reported and major progresses have been made in the understanding of physiopathology, screening, diagnosis, treatment, and molecular genetics of this inherited disease. Present knowledge on different aspects of DHPR deficiency, largely derived from authors' personal experience, is traced in this article., (Copyright 2003 Wiley Periodicals, Inc.)
- Published
- 2004
- Full Text
- View/download PDF